Personalized Hormone Dosing: Why One Dose Doesn’t Fit All

By CleopatraRX | Medically Reviewed by Manasa Murthy, PharmD | Updated July 2026

Key Takeaways

• Hormone levels vary widely from one woman to the next, so the same dose can produce very different results in two different bodies. Hormone therapy works best when it is individualized rather than standardized.
• Most commercially available hormones come in a small number of fixed doses. That leaves little room to fine-tune therapy to a specific woman.
• Some formats are harder to adjust than others: a patch releases hormone at a fixed, factory-set rate, while an oral dose can be titrated far more precisely.
• Compounding is a long-established, regulated pharmacy practice for individualized dosing. It is not a last resort, and it is not the same as the recent wave of online prescribing.
• CleopatraRX pairs individualized estriol and progesterone dosing, through PearlPAK®, with hands-on clinical care fitted to the woman, not the average.

Why Your Hormone Dose Was Never Fitted to You

If you are on hormone therapy and the brain fog still has not lifted, the problem may be the dose, and the fact that it was never chosen for you specifically.

Most commercially available hormones are built for population-level dosing. A manufacturer settles on a small set of fixed strengths that perform well, on average, across a large group of women, and those few options are what a prescriber has to work with. For some women, one of those doses lands close enough. For many others it does not, and the result is a frustration that has become very common: you are technically on hormones, but you do not feel right, your symptoms have not fully resolved, or you are living with side effects that do not seem to add up.

That gap between the standard dose and the woman taking it is the whole subject of this article. It is also the reason personalized hormone dosing matters more in hormone therapy than in almost any other kind of medicine.

Hormones Don’t Follow Averages

Most medications are designed around population-level outcomes. A dose is chosen because it works, on average, across thousands of people, and for a great many drugs that approach is perfectly sound. Hormones are the exception, because how a given dose behaves depends heavily on the individual taking it.

The scale of this variation is well documented. Give two women the identical estrogen patch and one can settle at roughly half the circulating level of the other, with both readings sitting comfortably inside the range considered normal. The pharmacology literature has long acknowledged that blood levels of these hormones vary widely between individuals, regardless of how the hormone is delivered.

Why the Same Dose Lands Differently

How much of a dose reaches your bloodstream, and what your body does with it once it arrives, is shaped by your metabolism, your liver and kidney function, your body composition, and how well you absorb it. Those factors vary considerably from one woman to the next. They can even shift within the same woman over the course of her life. Two women who are the same age can need meaningfully different amounts, because a body that clears hormones quickly and a body that clears them slowly will not respond to an identical dose in the same way.

Body size matters here too. Standardized doses tend to be calibrated to an average-sized body, so a smaller woman placed on that same dose can end up carrying more hormone than she actually needs. This is not a minor detail, because most hormone-related side effects come from having somewhat more hormone on board than the body requires, rather than too little.

When It’s Worth Revisiting Your Dose

Even a change you can see on a bathroom scale can move the target. A shift of around twenty pounds, in either direction, is generally enough that a thoughtful clinician would revisit the dose. In a moment when many women are losing or gaining weight rapidly on GLP-1 medications, that is no longer an unusual event. It is a standing reason to reconsider what a body now needs, rather than assuming last year’s dose still fits.

The Problem With Fixed Doses

Consider the estradiol patch. It is a genuinely good option, and it is the route many menopause clinicians reach for first. It also illustrates the limits of fixed dosing clearly, because it is manufactured in only a handful of strengths, roughly five, ranging from 0.025 to 0.1 mg per day. In everyday practice, many prescribers work from just one or two of those.

The patch is also harder to fine-tune than a pill, and the reason is built into how it works. A transdermal patch releases hormone at a fixed rate that is set by the patch itself, which is part of what makes its steady delivery appealing. But that same design means adjusting the dose usually comes down to switching to another fixed strength or trimming the patch’s surface area (not recommended), which is a blunt way to make a fine change. An oral dose is far more forgiving. It can be titrated to a specific milligram and changed from one prescription to the next, and when a compounding pharmacy prepares it, the increments can be finer still.

Progesterone Has the Same Problem

Progesterone runs into the same wall. Oral progesterone is commonly stocked in two strengths, 100 and 200 mg, with nothing in between. For a woman whose body does best on a dose that falls somewhere in the middle, or who tolerates the hormone but reacts to a filler or oil base in the standard capsule, the commercial shelf simply does not have an answer.

None of this is a knock on the patch or on commercial hormones, which work well for a large number of women. It is a description of a real constraint. A short menu of fixed doses cannot be matched to the full range of bodies that need them, and when your body falls between the available options, you are left rounding to the nearest one and hoping it is close enough.

A Different Molecule: ERα vs. ERβ

Personalization is not only a question of how much. Sometimes it is a question of which hormone.

Estrogen acts through two main receptors that behave quite differently. Estrogen receptor alpha, or ERα, is concentrated in breast and reproductive tissue and tends to drive cell growth. Estrogen receptor beta, or ERβ, is enriched in the brain and nervous system and tends to do the opposite. The estrogens differ in where they bind. Estradiol, the estrogen in most standard therapy, binds both receptors. Estriol binds preferentially to ERβ. Estriol is also a weaker estrogen, and unlike estradiol it does not convert to estrone in the body.

This distinction is the foundation of Dr. Rhonda Voskuhl’s work, and it did not begin with menopause. It began with multiple sclerosis. A professor of neurology at UCLA who has run an NIH-funded research program for nearly thirty years while still seeing patients every week, Voskuhl found that estriol — the estrogen the body produces in pregnancy — reduced relapses and helped preserve brain tissue in women with MS, in a randomized trial published in Lancet Neurology. Her lab later traced that protection to estrogen receptor beta in the brain’s support cells, and found the same mechanism at work in the aging female brain.

That path, from the patient to the mechanism and back to the patient, led to a direct hypothesis. If a brain-selective estrogen protects the brain in disease, it may help the majority of women who experience cognitive symptoms in menopause, where brain fog is rarely treated as a brain event at all.

Estradiol is effective for hot flashes, sleep, and bone, and for many women it is exactly the right choice. The point is not that one estrogen is stronger than another. It is that not all estrogens are alike. Estriol is another option in the toolkit — one more tool a clinician can reach for when its brain-first profile fits the woman in front of her, and matching the molecule to the goal is its own form of personalization.

Compounding Is How Medicine Gets Personalized

If the answer to fixed dosing is an individualized dose, compounding is how that dose gets made. And it is worth being clear about what compounding actually is, because it has picked up an unfair reputation lately.

Compounding is not new, and it is not fringe. Preparing a medicine for a specific patient is the oldest form of pharmacy, older than mass manufacturing itself. It is the same practice behind a liquid version of a pill made for a child who cannot swallow tablets, or a cream prepared without a dye a patient reacts to — not every body fits the standardized options, and compounding exists precisely for the ones that do not. It remains a routine, regulated part of practice today: under Section 503A of the federal Food, Drug, and Cosmetic Act, a compounding pharmacy prepares medications for an individual patient against a valid prescription, made by a licensed pharmacist, following United States Pharmacopeia standards and the oversight of state boards of pharmacy.

Why This Applies to Estriol

Estriol is a clear example of why the practice matters. It has a United States Pharmacopeia monograph, which is what allows a pharmacy to prepare it, and pharmaceutical companies do manufacture it, just not in the United States. Because it is not sold here as an FDA-approved standalone product, compounding is the legitimate route to it. That is a clinical rationale for another tool in a physician’s tool kit.

A Business-Model Problem, Not a Practice Problem

The recent skepticism around compounding says more about a business model than about the practice. A wave of online platforms has begun prescribing compounded products at scale, often on the strength of a short intake form and very little individual attention. That is a delivery-model problem, and it should not be confused with what a compounding pharmacy has always done: prepare a specific medicine, for a specific person, on a specific prescription. It is fair to note that compounded products are not FDA-approved and that menopause-specific trials for this approach are ongoing. That is a real consideration to weigh with a clinician, not a reason to dismiss an individualized option.

How CleopatraRX Individualizes Dosing

PearlPAK® is a compounded protocol of oral estriol and progesterone, built on Dr. Voskuhl’s research rather than on templates. Because it is compounded, both hormones can be prepared to fit the individual, and because it is taken orally, the dose can be adjusted precisely as a woman responds, rather than stepped between a few fixed strengths.

Progesterone is handled with the same care. It is not a fixed add-on. It can be started low and built gradually, and its form can be adjusted for women who tolerate the hormone but not a standard commercial capsule, which is often a matter of the base or filler rather than the progesterone itself.

The dose is only half of what personalization means here. The other half is the clinical care around it. Women in the program work with menopause-trained clinicians and nurses, with real consultation time rather than a checkbox form and an automatic refill. The first dose is treated as a starting point, not a verdict, and it is adjusted according to how a woman actually feels and functions over time. That combination, an individualized formulation and a clinician close enough to change it, is what it means to fit treatment to the woman instead of to an average.

Who PearlPAK® Is Designed For

Consider discussing PearlPAK® with your clinician if you:

• Experience brain fog, word-finding difficulty, or slowed processing as your primary concern.
• Have a family history of cognitive decline and want a brain-first approach.
• Have found that a standard, fixed-dose regimen has not fit your body, whether that means too much, too little, or side effects that do not add up.

Who Should Not Use PearlPAK®

PearlPAK® is not for everyone. Women with a personal history of estrogen-sensitive breast cancer, a history of blood clots or thromboembolism, unexplained vaginal bleeding, active liver disease, or a known sensitivity to estriol or progesterone should review their history carefully with a clinician before starting any hormone therapy.

As a compounded product, PearlPAK® is not FDA-approved, and has not been established as safer or more effective than FDA-approved hormone therapy. It is intended for use under the supervision of a qualified clinician.

Next Steps

1. Notice the pattern. If you are technically on hormone therapy but the fog has not lifted, or you are dealing with side effects that do not add up, that is worth raising rather than accepting.
2. Ask whether your dose was fitted to you, and whether it has been revisited after any meaningful change in weight, health, or medication.
3. If cognitive symptoms are your priority, ask specifically about oral estriol and whether its brain-first profile fits your goals.
4. Take the Voskuhl Menopause Brain Fog Assessment at cleopatrarx.com and connect with a clinician licensed in your state.

Frequently Asked Questions

Why can’t one standard dose work for everyone?

Because bodies absorb and process hormones differently. The same dose can produce very different blood levels in two women, so a starting dose is best understood as a first estimate that is refined over time, not a fixed answer.

Is compounded hormone therapy a last resort?

No. Compounding is a long-established, regulated pharmacy practice for preparing a medication in a dose or form a manufacturer does not offer. It is also the route to estriol, which is not sold as an FDA-approved standalone product in the United States.

Why estriol instead of estradiol?

Estriol is not a replacement for estradiol. It is a different estrogen that binds preferentially to ERβ in the brain and does not convert to estrone. It gives a clinician another option to consider based on the individual woman and her goals.

Why is a patch harder to individualize than a pill?

A patch releases hormone at a fixed, built-in rate and comes in only a few strengths, so adjusting it usually means switching strengths or trimming the patch (not recommended). An oral dose can be titrated much more precisely, and a compounded oral dose finer still.

How is a personalized dose decided and adjusted?

Through consultation and clinical follow-up. Dosing starts from a woman’s symptoms and history and is adjusted according to how she responds over time, rather than being set once and left alone.

References

1. Voskuhl RR, Wang H, Wu TC, et al. Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurology. 2016;15(1):35–46. doi:10.1016/S1474-4422(15)00322-1. View source

2. Itoh N, Itoh Y, Meyer CE, et al. Estrogen receptor beta in astrocytes modulates cognitive function in mid-age female mice. Nature Communications. 2023;14:6044. doi:10.1038/s41467-023-41723-7. View source

3. Estradiol transdermal system, USP — Prescribing Information. DailyMed, U.S. National Library of Medicine. Five dosage strengths (0.025, 0.0375, 0.05, 0.075, 0.1 mg/day); dosage adjustment guided by clinical response. View source

4. The range and variation in serum estradiol concentration in perimenopausal and postmenopausal women treated with transdermal estradiol in a real-world setting: a cross-sectional study. Menopause (Journal of The Menopause Society). 2025. View source

5. U.S. Food and Drug Administration. FD&C Act Provisions That Apply to Human Drug Compounding (Section 503A). View source

6. Rhonda R. Voskuhl, MD — Professor of Neurology, David Geffen School of Medicine at UCLA. View provider profile